18 August 2020: Clinical Research
Effects of a Secondary Prevention Combination Therapy with beta-Blocker and Statin on Major Adverse Cardiovascular Events in Acute Coronary Syndrome Patients
Ling Zhu 12ABCDEFG , Qianwei Cui 1BCEF , Ying Liu 3BCEF , Zhongwei Liu 1BCE , Yong Zhang 1BCF , Fuqiang Liu 1ACDEFG* , Junkui Wang 1ACDEFG*DOI: 10.12659/MSM.925114
Med Sci Monit 2020; 26:e925114
Supplementary Table 2 MACE of the study patients according to risk category of always beta-blocker and statin treatment.
| Total | No therapy | Beta-blocker mono-therapy | Statin mono-therapy | Co-therapy | P value | |
|---|---|---|---|---|---|---|
| n=636 | n=139 | n=71 | n=149 | n=277 | ||
| MACE | 98 (15.4) | 40 (28.8) | 14 (19.7) | 22 (14.8) | 22 (7.9) | |
| Cardiovascular death, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | – |
| Myocardial infarction, n (%) | 8 (1.3) | 1 (0.7) | 2 (2.8) | 1 (0.7) | 4 (1.4) | 0.531 |
| Ischemia-driven revascularization, n (%)* | 73 (11.5) | 31 (22.3) | 9 (12.7) | 16 (10.7) | 17 (6.1) | |
| Progress to NYHA III or IV, n (%) | 17 (2.7) | 7 (5.0) | 5 (7.0) | 2 (1.3) | 3 (1.1) | 0.008 |
| Stroke, n (%) | 14 (2.2) | 6 (4.3) | 0 (0) | 5 (3.4) | 3 (1.1) | 0.071 |
| * Included percutaneous coronary intervention and coronary artery bypass grafting. MACE – major adverse cardiac events; NYHA – New York Heart Association. | ||||||